We expect domestic growth to be in-line with the industry, while the US business to increase its contribution going forward. One specialty product launch in US every quarter to support better overall margins. Since the US sales is ~USD100mn lower than expectations, we are slightly tapering down our sales forecasts for FY19/20. We have reduced the run-rate of depreciation which has resulted in our EPS to increase by 17% for FY19 and 6.3% in FY20.expect Cipla's sales/EBITDA/net profit to grow at a CAGR of 12.5%/19%/31.7%, respectively, over FY18-20E. US growth the key for improvement in the EBITDA margins: Cipla continues to have...